PMID- 29958025
OWN - NLM
STAT- MEDLINE
DCOM- 20181121
LR  - 20181121
IS  - 1557-8593 (Electronic)
IS  - 1520-9156 (Linking)
VI  - 20
IP  - 7
DP  - 2018 Jul
TI  - Duration of Catheter Use in Patients with Diabetes Using Continuous Subcutaneous 
      Insulin Infusion: A Review.
PG  - 506-515
LID - 10.1089/dia.2018.0110 [doi]
AB  - Increasing proportions of patients with diabetes use continuous subcutaneous 
      insulin infusion (CSII) therapy mostly due to its clinical efficacy and 
      flexibility for insulin dosing and adjustments. Some challenges are nevertheless 
      associated with this technology. A key and underlooked component of CSII 
      technical difficulties is the subcutaneous catheter used to infuse insulin. 
      Several adverse events (AEs) have been experienced by patients in relation to 
      catheters, such as blockage, kinking, and insertion site reactions, including 
      irritation, infections, lipohypertrophies etc., all of which could compromise the 
      metabolic control. With the objective of minimizing these AEs, recommendations 
      for changing catheters every 2-3 days have historically been provided by 
      manufacturers based on reports derived from small studies and anecdotal data. The 
      aim of this review was to provide an updated analysis of current recommendations 
      and patients' practices in relation to frequency of catheter change. Our main 
      findings are: (1) adequately designed and powered studies investigating optimal 
      catheter wearing time are still lacking; (2) increasing catheter wearing time is 
      generally associated with increased frequency of catheter AEs; (3) however, 
      interpatient variability is large, with some individuals needing to change their 
      catheters every 2-3 days, whereas others probably being able to keep them in 
      place for longer periods without problems. Further research is thus warranted to 
      provide more solid and evidence-based recommendations while exploring 
      personalized approaches at the same time. Increasing catheter wear life without 
      significant side effects is an important goal to simplify CSII therapy and reduce 
      its associated costs and burdens.
FAU - Bonato, Lisa
AU  - Bonato L
AD  - 1 Research Platform on obesity, metabolism and diabetes, Institut de Recherches 
      Cliniques de Montreal (IRCM) , Montreal, Quebec, Canada .
FAU - Taleb, Nadine
AU  - Taleb N
AD  - 1 Research Platform on obesity, metabolism and diabetes, Institut de Recherches 
      Cliniques de Montreal (IRCM) , Montreal, Quebec, Canada .
AD  - 2 Department of Biomedical Sciences, Faculty of Medecine, Universite de Montreal 
      , Edouard-Montpetit, Montreal, Quebec, Canada .
FAU - Gingras, Veronique
AU  - Gingras V
AD  - 1 Research Platform on obesity, metabolism and diabetes, Institut de Recherches 
      Cliniques de Montreal (IRCM) , Montreal, Quebec, Canada .
AD  - 3 Department of Nutrition, Faculty of Medecine, Universite de Montreal , Chemin 
      de la Cote-Sainte-Catherine, Montreal, Quebec, Canada .
FAU - Messier, Virginie
AU  - Messier V
AD  - 1 Research Platform on obesity, metabolism and diabetes, Institut de Recherches 
      Cliniques de Montreal (IRCM) , Montreal, Quebec, Canada .
FAU - Gobeil, Fernand
AU  - Gobeil F
AD  - 4 Department of Pharmacology and Physiology, Faculty of Medicine and Health 
      Sciences, Universite de Sherbrooke , Sherbrooke, Quebec, Canada .
AD  - 5 Diabetes, obesity and cardiovscular complications axis, Research Center of the 
      Centre Hospitalier Universitaire de Sherbrooke , Sherbrooke, Quebec, Canada .
FAU - Menard, Julie
AU  - Menard J
AD  - 5 Diabetes, obesity and cardiovscular complications axis, Research Center of the 
      Centre Hospitalier Universitaire de Sherbrooke , Sherbrooke, Quebec, Canada .
FAU - Ardilouze, Jean-Luc
AU  - Ardilouze JL
AD  - 5 Diabetes, obesity and cardiovscular complications axis, Research Center of the 
      Centre Hospitalier Universitaire de Sherbrooke , Sherbrooke, Quebec, Canada .
AD  - 6 Endocrine Division, Department of Medicine, Faculty of Medicine and Health 
      Sciences, Universite de Sherbrooke , Sherbrooke, Quebec, Canada .
FAU - Rabasa-Lhoret, Remi
AU  - Rabasa-Lhoret R
AD  - 1 Research Platform on obesity, metabolism and diabetes, Institut de Recherches 
      Cliniques de Montreal (IRCM) , Montreal, Quebec, Canada .
AD  - 3 Department of Nutrition, Faculty of Medecine, Universite de Montreal , Chemin 
      de la Cote-Sainte-Catherine, Montreal, Quebec, Canada .
AD  - 7 Montreal Diabetes Research Center , Saint-Denis Montreal, Quebec, Canada .
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Diabetes Technol Ther
JT  - Diabetes technology & therapeutics
JID - 100889084
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Diabetes Mellitus, Type 1/*drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Insulin/administration & dosage
MH  - Insulin Infusion Systems/*adverse effects
MH  - Lipodystrophy/*etiology
MH  - Subcutaneous Tissue/*drug effects
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cannula
OT  - Catheter
OT  - Catheter adverse events
OT  - Catheter wear time
OT  - Continuous subcutaneous insulin infusion
OT  - Insulin pumps
EDAT- 2018/06/30 06:00
MHDA- 2018/11/22 06:00
CRDT- 2018/06/30 06:00
PHST- 2018/06/30 06:00 [entrez]
PHST- 2018/06/30 06:00 [pubmed]
PHST- 2018/11/22 06:00 [medline]
AID - 10.1089/dia.2018.0110 [doi]
PST - ppublish
SO  - Diabetes Technol Ther. 2018 Jul;20(7):506-515. doi: 10.1089/dia.2018.0110.